Dr. Radich is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1959 NE Pacific St
Seattle, WA 98195Phone+1 206-288-1000Fax+1 206-606-1025
Summary
- Dr. Jerald Radich is an oncologist in Seattle, WA at the Fred Hutchinson Cancer Research Center. He received his medical degree from University of California Davis School of Medicine and has been in practice 34 years. He specializes in hematologic oncology and is experienced in molecular genetics and stem cell transplantation.
Education & Training
- American College of Physicians2008
- Leukemia Society of America1991 - 1994
- University of Washington and the Fred Hutchinson Cancer Research Center1987 - 1990
- Veterans Administration Medical Center AffiliatedResidency, Chief Medical, 1986 - 1987
- V.A. HospitalChief Residency, Chief Medical, 1986 - 1987
- University of WashingtonResidency, Internal Medicine, 1984 - 1986
- University of WashingtonInternship, Internal Medicine, 1983 - 1984
- University of California, Davis, School of MedicineClass of 1983
- Harvard UniversityFellowship, 1977 - 1979
- Harvard School of Public HealthM.S, Epidemiology, 1979
- University of CaliforniaPostgraduate studies, Biology, 1976 - 1977
- University of CaliforniaB.A, Biology, Honors, 1972 - 1976
Certifications & Licensure
- WA State Medical License 1984 - 2026
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- NIH CA 18029: Project 4 2011
- NIH CA 114762 2010
- Join now to see all
Clinical Trials
- Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia Start of enrollment: 2017 Jul 14
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) Start of enrollment: 2024 Jun 18
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- 18 citationsEffectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision AnalysisUrsula Rochau, M. Kluibenschaedl, David D. Stenehjem, Kuo Kuan-Ling, Jerald P. Radich
Leukemia Research and Treatment. 2015-12-10 - 995 citationsInternational Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.Daniel A Arber, Attilio Orazi, Robert P Hasserjian, Michael J Borowitz, Katherine R Calvo
Blood. 2022-09-15 - 2397 citationsMassively parallel digital transcriptional profiling of single cellsGrace X.Y. Zheng, Jessica M. Terry, Phillip Belgrader, Paul Ryvkin, Zachary Bent
Nature Communications. 2017-01-16
Journal Articles
- Genomic Analyses Identify Recurrent MEF2D Fusions in Acute Lymphoblastic LeukaemiaMichael Borowitz, Hagop M Kantarjian, Cheryl L Willman, Stephen P Hunger, Selina M Luger, Clara D Bloomfield, Brent Wood, Jerald P Radich, Marina Konopleva, Stephen J ..., Nature
- Hairy cell leukemia has a B-cell genotype.Meyers FJ, Cardiff RD, Taylor C, Zuniga M, Radich JP, Hematol. Oncol. 2: 145-150
- Rare occurrence of N-ras point mutations in chronic myeloid leukemia.Collins SJ, Howard M, Andrews DF, Agura E, Radich J, Blood 73: 1028-1032
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Ultra-Accurate Assessment of Pretreatment ABL1 Kinase Domain (KD) Mutations in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic...Jerald P. Radich, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Accrual Barriers and Detection of Early Toxicity Signal in Older Less-Fit Patients Treated with Azacitidine and Nivolumab for Newly Diagnosed Acute Myeloid Leukemia (A...Jerald P. Radich, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Characterization of Clonal Dynamics after Hematopoietic Cell Transplantation Using Ultra-Sensitive Duplex SequencingJerald P. Radich, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- Patients, Borders, Money, and Mission: A Global Perspective of Chronic Myeloid Leukemia61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Analyses of Predictors of Durable Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase Following Frontline or Second-Line Nilotinib61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) Is Active and Well-Tolerated in Adults with Newly-Diagnosed Acute Lympho...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
- NIH Launches myeloMATCH Precision Medicine Trials for Myeloid CancersOctober 23rd, 2024
- myeloMATCH Program Opens Enrollment for Acute Myeloid Leukemia and MDSOctober 22nd, 2024
- S1712 Supports Adding Ruxolitinib to TKIs for CMLSeptember 20th, 2024
- Join now to see all
Grant Support
- Resistance And Relapse In Chronic Myeloid LeukemiaNational Cancer Institute2007–2011
- Genomic Analysis Of Gene Copy Number In Thyroid CancerNational Cancer Institute2005–2007
- Gene Expression Profile Of Progression &Response In CMLNational Cancer Institute2000–2003
- Genetic Markers In Prognosis And Residual DiseaseNational Cancer Institute2002
- Detection And Treatment Of Minimal Residual DiseaseNational Cancer Institute1997–2001
- Gene Expression Profile Of Progression And Response In CNational Cancer Institute1999
- Detection Of Minimal Residual Disease In Acute LeukemiaNational Cancer Institute1991–1993
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: